166 related articles for article (PubMed ID: 37031076)
1. Long-term Cardiovascular Risks of Gonadotropin-releasing Hormone Agonists and Antagonists: A Population-based Cohort Study.
Chan JSK; Lee YHA; Hui JMH; Liu K; Dee EC; Ng K; Tang P; Tse G; Ng CF
Clin Oncol (R Coll Radiol); 2023 Jun; 35(6):e376-e383. PubMed ID: 37031076
[TBL] [Abstract][Full Text] [Related]
2. Association between duration of gonadotrophin-releasing hormone agonist use and cardiovascular risks: A population-based competing-risk analysis.
Chan JSK; Tang P; Hui JMH; Lee YHA; Dee EC; Ng K; Liu K; Tse G; Ng CF
Prostate; 2022 Nov; 82(15):1477-1480. PubMed ID: 35915869
[TBL] [Abstract][Full Text] [Related]
3. Androgen Deprivation Therapy and Risk of Cardiovascular Disease in Patients With Prostate Cancer Based on Existence of Cardiovascular Risk.
Dragomir A; Touma N; Hu J; Perreault S; Aprikian AG
J Natl Compr Canc Netw; 2023 Feb; 21(2):163-171. PubMed ID: 36791755
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist.
Crawford ED; Hafron JM; Debruyne F; Wallis C; Chang S; Garnick MB
J Urol; 2024 Jan; 211(1):63-70. PubMed ID: 37796473
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan.
Shao YJ; Hong JH; Chen CK; Huang CY
Prostate Cancer Prostatic Dis; 2023 Dec; 26(4):722-729. PubMed ID: 35662291
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular Morbidity in a Randomized Trial Comparing GnRH Agonist and GnRH Antagonist among Patients with Advanced Prostate Cancer and Preexisting Cardiovascular Disease.
Margel D; Peer A; Ber Y; Shavit-Grievink L; Tabachnik T; Sela S; Witberg G; Baniel J; Kedar D; Duivenvoorden WCM; Rosenbaum E; Pinthus JH
J Urol; 2019 Dec; 202(6):1199-1208. PubMed ID: 31188734
[TBL] [Abstract][Full Text] [Related]
7. Gonadotropin-releasing hormone antagonist associated with lower cardiovascular risk compared with gonadotropin-releasing hormone agonist in prostate cancer: A nationwide cohort and in vitro study.
Chen DY; Su PJ; See LC; Liu JR; Chuang CK; Pang ST; Tseng CN; Chen SW; Hsieh IC; Chu PH; Lin YC; Hsu CL; Chang JW; Lin MS; Pang JS; Hsieh MJ; Huang WK
Prostate; 2021 Sep; 81(12):902-912. PubMed ID: 34196430
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist.
Albertsen PC; Klotz L; Tombal B; Grady J; Olesen TK; Nilsson J
Eur Urol; 2014 Mar; 65(3):565-73. PubMed ID: 24210090
[TBL] [Abstract][Full Text] [Related]
9. [Cardiovascular risk of androgen deprivation therapy for treatment of hormone-dependent prostate cancer : Differences between GnRH antagonists and GnRH agonists].
Tschöpe C; Kherad B; Spillmann F; Schneider CA; Pieske B; Krackhardt F
Herz; 2016 Dec; 41(8):697-705. PubMed ID: 27083586
[TBL] [Abstract][Full Text] [Related]
10. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.
Keating NL; O'Malley AJ; Freedland SJ; Smith MR
J Natl Cancer Inst; 2010 Jan; 102(1):39-46. PubMed ID: 19996060
[TBL] [Abstract][Full Text] [Related]
11. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis.
Bosco C; Bosnyak Z; Malmberg A; Adolfsson J; Keating NL; Van Hemelrijck M
Eur Urol; 2015 Sep; 68(3):386-96. PubMed ID: 25484142
[TBL] [Abstract][Full Text] [Related]
12. The cardiovascular effects of gonadotropin-releasing hormone antagonists in men with prostate cancer.
Cirne F; Aghel N; Petropoulos JA; Klotz L; Lenihan DJ; Saad F; Pinthus J; Leong DP
Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):253-262. PubMed ID: 33470403
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular Toxicity of Androgen Deprivation Therapy.
Boland J; Choi W; Lee M; Lin J
Curr Cardiol Rep; 2021 Jul; 23(8):109. PubMed ID: 34216282
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular risks of chemo-immunotherapy for lung cancer: A population-based cohort study.
Chan JSK; Tang P; Ng K; Dee EC; Lee TTL; Chou OHI; Lee YHA; Lau DHH; Liu T; Tse G
Lung Cancer; 2022 Dec; 174():67-70. PubMed ID: 36334359
[TBL] [Abstract][Full Text] [Related]
15. Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists-a nationwide population-based cohort study based on 2010-2013 French Health Insurance data.
Scailteux LM; Vincendeau S; Balusson F; Leclercq C; Happe A; Le Nautout B; Polard E; Nowak E; Oger E
Eur J Cancer; 2017 May; 77():99-108. PubMed ID: 28390298
[TBL] [Abstract][Full Text] [Related]
16. Differences in sex hormone recovery profile after cessation of 12-week gonadotropin-releasing hormone antagonist versus agonist therapy.
Sasaki H; Miki K; Tashiro K; Mori K; Urabe F; Fukuokaya W; Kimura T; Sato S; Takahashi H; Aoki M; Egawa S
Andrology; 2022 Feb; 10(2):270-278. PubMed ID: 34510814
[TBL] [Abstract][Full Text] [Related]
17. Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials.
Abufaraj M; Iwata T; Kimura S; Haddad A; Al-Ani H; Abusubaih L; Moschini M; Briganti A; Karakiewicz PI; Shariat SF
Eur Urol; 2021 Jan; 79(1):44-53. PubMed ID: 32605859
[TBL] [Abstract][Full Text] [Related]
18. [Cardiovascular risks of androgen deprivation therapy for prostate cancer].
Miller K
Urologe A; 2016 May; 55(5):627-31. PubMed ID: 27003571
[TBL] [Abstract][Full Text] [Related]
19. Update on cardiovascular and metabolic risk profiles of hormonal agents used in managing advanced prostate cancer.
Higano CS
Urol Oncol; 2020 Dec; 38(12):912-917. PubMed ID: 32900627
[TBL] [Abstract][Full Text] [Related]
20. Anti-androgen monotherapy versus gonadotropin-releasing hormone agonists in men with advanced, non-metastatic prostate cancer: a register-based, observational study.
Thomsen FB; Bosco C; Garmo H; Adolfsson J; Hammar N; Stattin P; Van Hemelrijck M
Acta Oncol; 2019 Jan; 58(1):110-118. PubMed ID: 30375907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
